Dietary health supplements have been increasingly used in the treatment of a variety of conditions. During the previous decades, L-arginine has been reported to have beneficial effects on male reproductive functions. Arginine is an amino acid that is important for being a precursor for the synthesis of nitric oxide, and playing a role in the regulation of blood pressure. The aim of this paper is to review L-arginine research findings relevant to its use in male reproductive abnormalities.

Conclusion and Expert Opinion: A variety of agents have been used in the treatment of poor semen quality of unknown etiology (Idiopathic) with a beneficial effect including mesterolone, zinc sulphate, coenzyme Q10, vitamin E, folic acid, pentoxifylline, and L-carnitine. A beneficial effect of arginine on oligospermia has been suggested as early as 1947. There is convincing research evidence suggesting that L-arginine can improve male reproductive abnormalities and can be useful in the treatment of some forms male infertility and erectile dysfunction. The addition of a safe therapeutic supplement to the already known therapeutic armamentarium is desirable. The current evidence-based opinion suggests that because L-arginine is safe and can be beneficial when used in patients with male reproductive abnormalities, to be aware of such potentially important therapy.

• L-arginine; Male Reproductive Abnormalities; Expert Opinion

Al Mosawi AJ (2024) The Use of L-Arginine in Male Reproductive Abnormalities: an Educational Article and Expert Opinion. JSM Med Case Rep 6(1): 1012.

The use of health supplements in the treatment of variety of conditions has been increasingly suggested [1-6]. Arginine is an amino acid that is important for being a precursor for the production of nitric oxide, and for playing a role in the regulation of blood pressure, and it has been increasingly used as a health supplement for having beneficial effects in a variety of conditions. L-arginine has been recognized as safe (GRAS-status) when taken in an oral dose of up to 20 g daily [7,8].

In 1886, Ernst Schulze (Figure-1A) and Ernst Steiger reported the isolation of arginine from yellow lupin seedlings and they called it arginine after “argyrols”, a Greek word means silver, because of the silver-white color of arginine nitrate crystals [9]. In 1897, Ernst Schulze and Ernst Winterstein (Figure-1B) clarified the structure of arginine, and in 1899, they synthesized it from ornithine and cyanamide [10, 11].

Figure 1A: Ernst Schulze (July 31, 1840-June 15, 1912), a German chemist.

Figure 1B: Ernst Winterstein (1865-1949), a German chemist.

A beneficial effect of arginine on oligospermia has been suggested as early as 1947 [12-14]. During the 1950s and 1960s, several authors including Giarola and Ballerio in 1959, and Pazzaglia and Poggio in 1965 reported the use of arginine in treatment of seminal deficiency [14,15].In 1967; Bernard reported the treatment of oligo-asthenospermia with arginine [16]. In 1975, Keller and Polakoski reported that L-arginine can stimulate human sperm motility in vitro [17].

In 1979, Papp, et al. reported a study which included 40 patients who had normal semen count, oligospermia or azoospermia. Low arginine content was found in patients with oligospermia and azoospermia, and was attributed to higher arginase activity and to higher conversion of arginine to Guanidinoacetic acid [18]. In 1993, Méndez and Hernández emphasized that L-arginine is the precursor of the polyamines putrescine, spermidine and spermine which are important in the initiation of the sperm motility processes [19]. In 1994, Scibona, et al. reported 40 infertile male patients who had a spermatozoa count of more than 20 million/ milliliter (Normal count more than 15 million sperm per milliliter or more than 39 million sperm per ejaculate) , but a reduced sperm motility that was not related to infection or to immune disorders. The patients were treated with oral L-arginine (80 ml of 10%) daily for six months. Treatment was associated with improved sperm motility without any side-effects [20].

In 1995, Aydin and colleagues reported the treatment of 15 patients who had oligospermia and asthenospermia with L-arginine for at least 12 weeks, and three pregnancies were achieved [21]. In 1999, Chen, et al. reported a placebo-controlled study which included fifty patients with organic erectile dysfunction. 29 patients received oral L-arginine, 5 grams daily, and 21 patients received placebo. Nine (31%) of the patients who received L-arginine, and two of 17 patients who received placebo experienced marked subjective improvement in their sexual function. The beneficial effect of L-arginine was attributed to improved nitric oxide production [22].

In 2022, Menafra, et al reported a placebo-controlled study which included 98 patients who had erectile dysfunction attributed to vasculogenic causes. 51 patients received oral L-arginine, 6 grams daily for three months, and 47 patients received placebo. Treatment with L-arginine was associated with marked improvement in erectile dysfunction [23]. Male reproductive abnormalities with poor semen quality (Count and motility) have some times been attributed to epididymoprostato-vesiculitis which can be recognized generally by finding 5 or more pus cells (White blood cells) per high power field in the semen. Epididymo-prostato-vesiculitis associated with associated with poor semen quality is generally treated with antibiotics such as minocycline and norfloxacin [24-26]. A variety of agents have been used in the treatment of poor semen quality of unknown etiology (Idiopathic) with a beneficial effect, including mesterolone, zinc sulphate, coenzyme Q10, vitamin E, folic acid, pentoxifylline, and L-carnitine [27-33].

The addition of a safe therapeutic supplement to the already known therapeutic armamentarium is desirable. The current evidence-based opinion suggests that because L-arginine is safe and can be beneficial when used in patients with male reproductive abnormalities, it is important for physicians treating patients with male reproductive abnormalities to be aware of such potentially important therapy.

The author has the sketches included in this paper.

1. Al-Mosawi AJ. The uses of L-Carnitine in cardiology. International Journal of Biomed Research (ISSN: 2690-4861). 2021; 1: 1-5.
2. Al-Mosawi AJ. The Use of Fenugreek Supplementation in Diabetes. Scientific Research Journal of Clinical and Medical Sciences (p-ISSN: 2788-8843, e-ISSN: 2788-8851). 2021; 1: 9-13.
3. Al-Mosawi AJ. The use of L-Carnitine in Male Reproductive Abnormalities: The Available Evidence. International Journal of Clinical and Medical Education Research (ISSN: 2832-7705). 2022; 1: 150-152.
4. Al-Mosawi AJ. The use of alpha-lipoic acid supplementation in diabetes: The available Evidence. Journal of Clinical Trails and Bioavailability Research (e-ISSN: 2836-5836). 2022; 1: 1-6.
5. Al-Mosawi AJ. The use of cinnamon supplementation in diabetes: Research evidence and expert opinion. Journal of Clinical Trails and Bioavailability Research (e-ISSN: 2836-5836). 2022; 1: 1-4.
6. Al-Mosawi AJ. The Use of Coenzyme Q10 in Hypertension: An Educational Article and Expert Opinion. Medical Journal of Clinical Trials & Case Studies (ISSN: 2578-483 8). 2023; 7: 1-2.
7. Al-Mosawi AJ. L-arginine research progress.1st ed., Saarbrücken; LAP Lambert Academic Publishing: (ISBN: 978-3-8484-9807-9). 2012.
8. Al-Mosawi AJ. The use of L-Arginine in hypertension: An educational article and expert opinion. Journal of Innovations in Medical Research (ISSN: 2788-7022). 2023; 2: 8-12.
9. Schulze E, Steiger E. Ueber das Arginin [On arginine]. Zeitschrift für Physiologische Chemie. 1887; 11: 43-65.
10. Schulze E, Winterstein E. Ueber ein Spaltungs-product des Arginins [On a cleavage product of arginine]. Berichte der Deutschen Chemischen Gesellschaft. 1897; 30: 2879-2882.
11. Schulze E, Winterstein E. Ueber die Constitution des Arginins [On the constitution of arginine]. Berichte der Deutschen Chemischen Gesellschaft. 1899; 32: 3191-3194.
12. Guterman HS. Influence of arginine on oligospermia. Proc Soc Exp Biol Med. 1947; 65:176-178.
13. Garrigues JC. Arginine et infertilité masculine [Arginine and male sterility]. Therapie. 1953; 8: 693-697.
14. Giarola A, Ballerio C. [Modern therapies of seminal deficiency; arginine and other amino acids]. Ann Ostet Ginecol. 1959; 81: 211- 325.
15. Pazzaglia L, Poggio A. arginine therapy in treatment of seminal deficiencies. Minerva Ginecol. 1965; 17: 16-20.
16. Bernard I. Le traitement des oligoasthénospermies par l’arginine [Treatment of oligoasthenospermia by arginine]. J Med Bord. 1967; 144: 293-296.
17. Keller DW, Polakoski KL. L-arginine stimulation of human sperm motility in vitro. Biol Reprod. 1975; 13:154-157.
18. Papp G, Grof J, Molnár J, Jambor E. Importance of arginine content and arginase activity in fertility. Andrologia. 1979; 11: 37-41.
19. Méndez JD, Hernández MP. Effect of L-arginine and polyamines on sperm motility. Ginecol Obstet Mex. 1993; 61: 229-234.
20. Scibona M, Meschini P, Capparelli S, Pecori C, Rossi P, Menchini Fabris GF. L-arginine and male infertility. Minerva Urol Nefrol. 1994; 46: 251-253.
21. Aydin S, Inci O, Alagöl B. The role of arginine, indomethacin and kallikrein in the treatment of oligoasthenospermia. Int Urol Nephrol. 1995; 27: 199-202.
22. Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int. 1999; 83: 269-273.
23. Menafra D, de Angelis C, Garifalos F, Mazzella M, Galdiero G, Piscopo M, et al. Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. J Endocrinol Invest. 2022; 45: 941-961.
24. Comhaire FH, Rowe PJ, Farley TM. The effect of doxycycline in infertile couples with male accessory gland infection: a double blind prospective study. Int J Androl. 1986; 9: 91-98.
25. Malallah YA, Zissis NP. Effect of minocycline on the sperm count and activity in infertile men with high pus cell count in their seminal fluid. J Chemother. 1992; 4: 286-289.
26. Arakawa S, Takagi S, Maeda H, Ka S, Matsumoto O, Kamidono S, et al. Clinical study of norfloxacin in the treatment of acute epididymitis. Hinyokika Kiyo. 1989; 35: 1089-1095.
27. Bhathena RK, Jassawalla MJ, Patel DN. The effects of mesterolone on sperm count in idiopathic oligospermia. Int J Fertil. 1987; 32: 306- 308.
28. Omu AE, Dashti H, Al-Othman S. Treatment of asthenozoospermia with zinc sulphate: andrological, immunological and obstetric outcome. Eur J Obstet Gynecol Reprod Biol. 1998; 79:179-184.
29. Safarinejad MR. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol. 2009; 182: 237-248.
30. Chen XF, Li Z, Ping P, Dai JC, Zhang FB, Shang XJ. Efficacy of natural vitamin E on oligospermia and asthenospermia: a prospective multi- centered randomized controlled study of 106 cases. Zhonghua Nan Ke Xue. 2012; 18: 428-431.
31. Huang WJ, Lu XL, Li JT, Zhang JM. Effects of folic acid on oligozoospermia with MTHFR polymorphisms in term of seminal parameters, DNA fragmentation, and live birth rate: a double-blind, randomized, placebo-controlled trial. Andrology. 2020; 8: 110-116.
32. Al-Mosawi AJ. The Use of Pentoxifylline in Male Reproduction Abnormalities. Scientific Research Journal of Clinical and Medical Sciences (p-ISSN: 2788-8843, e-ISSN: 2788-8851). 2021; 1: 1-3.
33. Al-Mosawi AJ. The use of L-Carnitine in Male Reproductive Abnormalities: The Available Evidence. International Journal of Clinical and Medical Education Research (ISSN: 2832-7705). 2022; 1: 150-152.